- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04305548
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma (ISG-MCS)
September 12, 2023 updated by: Italian Sarcoma Group
Phase II Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)
Study Overview
Detailed Description
Prospective, uncontrolled, multicenter, Italian, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic), HEY1-NCOA2 positive MCS) , pre-treated with anthracycline-based chemotherapy.
Study Type
Interventional
Enrollment (Estimated)
16
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Silvia Stacchiotti, MD
- Phone Number: 2804 39022390
- Email: silvia.stacchiotti@istitutotumori.mi.it
Study Locations
-
-
-
Bologna, Italy, 40136
- Recruiting
- Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors
-
Contact:
- Toni Ibrahim, MD
- Phone Number: 199 +390516366
- Email: toni.ibrahim@ior.it
-
Principal Investigator:
- Toni Ibrahim, MD
-
Milan, Italy, 20133
- Recruiting
- Fondazione IRCSS Istituto Nazionale dei Tumori
-
Contact:
- Silvia Stacchiotti, MD
- Phone Number: +39022390
- Email: silvia.stacchiotti@istitutotumori.mi.it
-
Principal Investigator:
- Silvia Stacchiotti, MD
-
Palermo, Italy
- Recruiting
- Ospedale Giaccone
-
Principal Investigator:
- Giuseppe Badalamenti, MD
-
Contact:
- Giuseppe Badalamenti, MD
- Email: giuseppe.badalamenti@unipa.it
-
Roma, Italy, 00128
- Recruiting
- Istituti Fisioterapici Ospitalieri - Ospedale Regina Elena
-
Contact:
- Virginia Ferraresi, MD
- Email: virginia.ferraresi@ifo.it
-
-
Firenze
-
Prato, Firenze, Italy, 59100
- Recruiting
- Nuovo Ospedale di Prato
-
Contact:
- Giacomo G. Baldi, MD
- Phone Number: 4766 0039057443
- Email: giacomogiulio.baldi@uslcentro.toscana.it
-
Principal Investigator:
- Giacomo G. Baldi, MD
-
-
RM
-
Roma, RM, Italy, 00128
- Not yet recruiting
- Policlinico Universitario Campus Biomedico
-
Principal Investigator:
- Bruno Vincenzi, MD
-
Contact:
- Bruno Vincenzi, MD
- Phone Number: 1123 003906-22541
- Email: b.vincenzi@unicampus.it
-
-
Torino
-
Candiolo, Torino, Italy, 10060
- Recruiting
- Fondazione Del Piemonte Per L'Oncologia Ircc Candiolo
-
Principal Investigator:
- Giovanni Grignani, MD
-
Contact:
- Sandra Aliberti, MD
- Phone Number: 3623 0039-011-993
- Email: sandra.aliberti@ircc.it
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 16 years old
- Histological centrally confirmed diagnosis of skeletal or extra-skeletal MCS with the documented presence of HEY1-NCOA2 fusion
- Locally advanced disease and/or metastatic disease
- Measurable or evaluable disease with RECIST v1.1
- Evidence of progression by RECIST v1.1 during the 6 months before study entry
- Patients must be pre-treated with at least one prior chemotherapy treatment containing anthracyclines for the advanced phase of disease and with a maximum of 3 lines
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
- Adequate bone marrow function
- Adequate organ function
- Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation each cycle of chemotherapy.
- Cardiac ejection fraction ≥50% as measured by echocardiogram
- No history of arterial and/or venous thromboembolic event within the previous 12 months
- The patient or legal representative must be able to read and understand the informed consent form and must have been willing to give written informed consent and any locally required authorisation before any study-specific procedures, including screening evaluations, sampling, and analyses.
- Any other factors, that, at judgment of investigator, could affect the safety of the patients according to the available trabectedin safety data
Exclusion Criteria:
- Other primary malignancy with <5 years clinically assessed disease free interval, except basal cell skin cancer, cervical carcinoma in situ or other neoplasm judged to entail a low risk of relapse
- Previous treatment with radiation therapy within 14 days of first day of study drug dosing, or patients who have not recovered from adverse events due to agents previously administered
- Previous radiotherapy to 25% of the bone marrow
- Major surgery within 2 weeks prior to study entry
- Participation in another clinical study with an investigational product, which last dose was taken less than 4 weeks prior to the start of the treatment.
- Persistent toxicities (≥ grade 2) with the exception of alopecia, caused by previous anticancer therapies.
- Pregnancy or breast feeding
- Grade III/IV cardiac problems as defined by the New York Heart Association Criteria
- Medical history of arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within 6 months prior to the initiation of study treatment
- Known brain metastasis
- Known chronic liver disease (i.e. chronic active hepatitis and cirrhosis)
- Known diagnosis oh human deficiency virus (HIV) infection
- Active or chronic hepatitis B or C requiring treatment with antiviral therapy
- Medical history of hemorrhage or a bleeding event ≥ Grade 3 within 4 weeks prior to the initiation of study treatment
- Evidence of any other serious or unstable illness, or medical, psychological, or social condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results
- Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
- Expected non-compliance to medical regimens
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Trabectedin
Trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion
|
Treatment with trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall tumour Response Rate, according to RECIST v 1.
Time Frame: At weeks 6
|
Response rate according Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
|
At weeks 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Choi criteria response rate
Time Frame: At weeks 6, 12,18, 30, 42
|
Response rate according Choi criteria
|
At weeks 6, 12,18, 30, 42
|
Overall Survival
Time Frame: At 3 and 5 years
|
Proportion of patients who are still alive at 36 and 60 months after have started the treatment
|
At 3 and 5 years
|
Progression Free Survival (PFS)
Time Frame: At 3 and 5 years
|
Survival without disease progression
|
At 3 and 5 years
|
Clinical Benefit Rate
Time Frame: Month 6
|
Proportion of patient alive, without disease progression, after 6 months of treatment.
|
Month 6
|
Duration of response
Time Frame: At weeks 6, 12,18, 30, 42
|
Duration of time between the date of first documented response and the date of first documented progression or death due to any cause
|
At weeks 6, 12,18, 30, 42
|
Adverse events related to the treatment
Time Frame: Week 3, week 6, week 9, week 12, week 18, week 24, week 36, week 48, week 60, week 72
|
Safety in term of grading of adverse event is evaluate from the first treatment dose throughout the study according to CTCAE 5.0
|
Week 3, week 6, week 9, week 12, week 18, week 24, week 36, week 48, week 60, week 72
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Silvia Stacchiotti, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lee AF, Hayes MM, Lebrun D, Espinosa I, Nielsen GP, Rosenberg AE, Lee CH. FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma. Appl Immunohistochem Mol Morphol. 2011 May;19(3):233-8. doi: 10.1097/PAI.0b013e3181fd6697.
- Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, Dal Cin P, Antonescu CR, Singer S, Hameed M, Bovee JV, Hogendoorn PC, Socci N, Ladanyi M. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer. 2012 Feb;51(2):127-39. doi: 10.1002/gcc.20937. Epub 2011 Oct 27.
- Morioka H, Takahashi S, Araki N, Sugiura H, Ueda T, Takahashi M, Yonemoto T, Hiraga H, Hiruma T, Kunisada T, Matsumine A, Susa M, Nakayama R, Nishimoto K, Kikuta K, Horiuchi K, Kawai A. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC Cancer. 2016 Jul 14;16:479. doi: 10.1186/s12885-016-2511-y.
- Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, Pilotti S, Mantovani R. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009 Feb;8(2):449-57. doi: 10.1158/1535-7163.MCT-08-0848. Epub 2009 Feb 3.
- Huvos AG, Rosen G, Dabska M, Marcove RC. Mesenchymal chondrosarcoma. A clinicopathologic analysis of 35 patients with emphasis on treatment. Cancer. 1983 Apr 1;51(7):1230-7. doi: 10.1002/1097-0142(19830401)51:73.0.co;2-q.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 14, 2021
Primary Completion (Estimated)
September 1, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
March 9, 2020
First Submitted That Met QC Criteria
March 11, 2020
First Posted (Actual)
March 12, 2020
Study Record Updates
Last Update Posted (Actual)
September 13, 2023
Last Update Submitted That Met QC Criteria
September 12, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISG-MCS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mesenchymal Chondrosarcoma
-
Leiden University Medical CenterCompletedMyxoid Liposarcoma | Mesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Conventional ChondrosarcomaSpain, Netherlands
-
National Cancer Institute (NCI)Active, not recruitingMesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Clear Cell Chondrosarcoma | Locally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Primary Central ChondrosarcomaFrance
-
Sarcoma Alliance for Research through CollaborationCompletedLiposarcoma | Osteogenic Sarcoma | Ewing/Ewing-like Sarcoma | Rhabdomyosarcoma | Mesenchymal ChondrosarcomaUnited States
-
Klinikum StuttgartKlinikum Kassel GmbH (COSS-Biobank)Not yet recruitingOsteosarcoma | High Grade Sarcoma | Recurrent Osteosarcoma | Bone Sarcoma | Undifferentiated Pleomorphic Sarcoma | Bone Tumor | Extraskeletal Osteosarcoma | Osseous Sarcoma | Parosteal Osteosarcoma | Osteoblastic Osteosarcoma | Chondroblastic Osteosarcoma | Fibroblastic Osteosarcoma | Conventional Osteosarcoma | Conventional... and other conditions
-
National Cancer Institute (NCI)Active, not recruitingDedifferentiated Chondrosarcoma | Central Chondrosarcoma, Grade 2 | Central Chondrosarcoma, Grade 3 | Metastatic Clear Cell Sarcoma of Soft Tissue | Metastatic Primary Central Chondrosarcoma | Unresectable Primary Central ChondrosarcomaUnited States, Canada
-
National Cancer Institute (NCI)SuspendedMetastatic Primary Central Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Locally Advanced Unresectable Primary Central ChondrosarcomaUnited States
-
National Research Center for Hematology, RussiaUnknownMesenchymal Stem Cell TransplantationRussian Federation
-
University of AarhusCompletedMesenchymal Stem Cells
-
Memorial Sloan Kettering Cancer CenterAgios Pharmaceuticals, Inc.RecruitingChondrosarcoma | IDH1 Gene Mutation | Chondrosarcoma, Grade 2 | Chondrosarcoma, Grade 3United States
Clinical Trials on Trabectedin
-
Italian Sarcoma GroupAstraZeneca; PharmaMarActive, not recruitingAdvanced Soft Tissue SarcomaItaly
-
Italian Sarcoma GroupPharmaMarWithdrawnLeiomyosarcoma | Liposarcoma | Synovial SarcomaItaly
-
PharmaMar, SpainCompletedSoft Tissue SarcomaGermany
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Completed
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedSarcomaUnited States
-
European Organisation for Research and Treatment...CompletedSarcoma | Small Intestine Cancer | Ovarian Cancer | Brain and Central Nervous System Tumors | Endometrial Cancer | Gastrointestinal Stromal Tumor
-
European Organisation for Research and Treatment...CompletedUnspecified Adult Solid Tumor, Protocol SpecificFrance, Spain, Denmark, Netherlands, Norway, Belgium, United Kingdom, Israel, Italy, Switzerland, Germany, Austria, Greece, Portugal
-
University of Colorado, DenverWithdrawn
-
PharmaMarCompletedRelapsed Ovarian CancerSpain, France, Italy, Belgium, Germany
-
Grupo Español de Investigación en Cáncer de OvarioCompleted